Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS on Claritin

This article was originally published in The Tan Sheet

Executive Summary

"The switch of Claritin to OTC status simultaneously slowed overall sales of prescription drugs (before rebates) by .8 percentage points and sped up growth in OTC sales 4.4%, the highest rate of growth since 1999," according to a report issued by the Centers for Medicare & Medicaid Services Office of the Actuary Jan. 11. The switch of the Schering-Plough allergy remedy also factored into health plans' decision to increase co-payments for other non-sedating antihistamines, the report adds...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel